Melinda L. Telli, MD, on Breast Cancer: Neoadjuvant Talazoparib for Early HER2-Negative Disease

July 15, 2021 By The ASCO Post Staff

Melinda L. Telli, MD, of Stanford University, discusses results of a phase II study on neoadjuvant talazoparib in germline BRCA1/2 mutation–positive, early HER2-negative breast cancer. In this setting, talazoparib monotherapy was active and yielded pathologic complete response rates comparable to those observed with combination anthracycline and taxane-based chemotherapy regimens (Abstract 505).

Related Content